Literature DB >> 34295066

Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute.

Amit Sehrawat1, Gyanendra Swaroop Mittal2, Deepak Sundriyal1, Anushree Chaturvedi3, Deni Gupta4.   

Abstract

Cancer-associated deep venous thrombosis (DVT) and venous thromboembolism (VTE) are exceedingly common in patients with cancer. One-fifth of DVT events occur in patients with cancer and it is the second leading cause of death in patients with cancer after cancer itself. Data on DVT in cancer patients on medical therapy, especially from Indian experiences, are sparse. Here, we present our experience in ambulatory patients with solid organ cancer. The purpose of the study was to study the incidence of DVT in cancer patients on medical therapy and to analyze probable DVT risk factors. This study was a hospital-based single-arm retrospective collection and analysis of hospital records from patients receiving medical therapy on an outpatient and short-stay basis. From January 2016 to February 2017, adult solid organ cancer patients attending the medical oncology outpatient department (OPD), receiving active anticancer treatment, either oral or injectable, were included. The data was retrieved from the medical records department and the department of radiology. Descriptive statistics were used to analyze the data. Twenty-nine out of 1190 patients were documented to have developed DVT during the study period. The incidence of DVT in the outpatient settings was 2.4%, and DVT associated with venous access device in situ was seen in 4.05% (20/493) of the patients. Gynecological, breast, and hepatobiliary malignancies comprised most of the cases. Cancer patients are clearly at increased risk for DVT, but this risk is highly variable. It differs between subgroups of cancer patients. Five points Khorana risk model can predict risk for DVT in the ambulatory cancer patients receiving chemotherapy; however, the routine use of thromboprophylaxis in all cancer patients is not recommended. High-risk patients especially those with venous access devices need careful evaluation and counseling for prompt reporting and recognition of venous thrombosis. © Indian Association of Surgical Oncology 2021.

Entities:  

Keywords:  Cancer-associated thromboembolism; Deep venous thrombosis; Thromboprophylaxis; Venous access device; Venous thromboembolism

Year:  2021        PMID: 34295066      PMCID: PMC8272765          DOI: 10.1007/s13193-021-01303-x

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  13 in total

Review 1.  Cancer and thrombosis: implications of published guidelines for clinical practice.

Authors:  A A Khorana
Journal:  Ann Oncol       Date:  2009-06-26       Impact factor: 32.976

Review 2.  Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score.

Authors:  Gregory C Connolly; Alok A Khorana
Journal:  Thromb Res       Date:  2010-04       Impact factor: 3.944

3.  Deep Vein Thrombosis in Indian Cancer Patients Undergoing Major Thoracic and Abdomino-Pelvic Surgery.

Authors:  Ashish Jakhetiya; Nootan Kumar Shukla; S V Suryanarayana Deo; Pankaj Kumar Garg; Sanjay Thulkar
Journal:  Indian J Surg Oncol       Date:  2016-06-06

4.  Pulmonary embolism in cancer patients.

Authors:  S P Sawant; S Banumathy; A Daddi; A A Dhir
Journal:  Indian J Cancer       Date:  2012 Jan-Mar       Impact factor: 1.224

5.  Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy.

Authors:  P D Stein; J W Henry
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

6.  Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis.

Authors:  K M Moser; P F Fedullo; J K LitteJohn; R Crawford
Journal:  JAMA       Date:  1994-01-19       Impact factor: 56.272

7.  Development and validation of a predictive model for chemotherapy-associated thrombosis.

Authors:  Alok A Khorana; Nicole M Kuderer; Eva Culakova; Gary H Lyman; Charles W Francis
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

8.  Impact of thrombosis on standard treatment in solid tumors.

Authors:  Chandran K Nair; Atanu Bhattacharjee; Vineetha Raghavan; Satheesh Babu; Satheesan Balasubramanian
Journal:  Thromb Res       Date:  2015-09-25       Impact factor: 3.944

Review 9.  Catheter-related thrombosis in cancer patients.

Authors:  Jim Murray; Elizabeth Precious; Raza Alikhan
Journal:  Br J Haematol       Date:  2013-07-15       Impact factor: 6.998

Review 10.  Recurrent venous thromboembolism: what is the risk and how to prevent it.

Authors:  Gualtiero Palareti
Journal:  Scientifica (Cairo)       Date:  2012-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.